{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 7 of 122', 'The maximum severity of symptoms occurring at each challenge dose of peanut protein during the', 'OLFC, assessed by tabulating the number and percentage of subjects by maximum severity at the', 'OLFC and by treatment group', 'The proportion of subjects successfully completing the RWPC with no or mild symptoms after', 'approximately 13 months of AR101 treatment, assessed by presenting the response rate and associated', '95% CI using an exact Clopper-Pearson CI', 'The maximum severity of symptoms during the RWPC after approximately 13 months of AR10', 'treatment in eligible subjects who consented to the RWPC, assessed by tabulating the number and', 'percentage of subjects by maximum severity', 'Safety Analyses:', 'All safety analyses will be performed using the safety population, defined as all subjects who receive any', 'randomized study treatment. Safety data will be listed and summarized by treatment received. Descriptive', 'statistics will be used.', 'Safety data will be collected from signed informed consent/assent through early discontinuation or study exit,', 'and through at least 30 days after early discontinuation or study exit for subjects with unresolved adverse', 'events or through at least 6 months after early discontinuation or study exit for subjects with GI adverse', 'events of interest. Adverse events will be classified by system organ class and coded to preferred term using', 'the Medical Dictionary for Regulatory Activities (MedDRA). Adverse events will be classified by severity', 'using the Consortium of Food Allergy Research (CoFAR) grading system for allergic reactions, European', 'Academy of Allergy and Clinical Immunology (EAACI) guidelines for anaphylaxis, and National Cancer', 'Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) for all other adverse events.', 'The safety of AR101 treatment versus standard of care alone will be evaluated by the analysis of the', 'incidence of nonserious and serious adverse events, severity of adverse events, incidence and severity of', 'treatment-related adverse events, incidence of dose modifications (AR101 treatment only), and incidence of', 'early treatment discontinuation due to adverse events and due to chronic or recurrent GI adverse events.', 'Separate summaries will be presented for anaphylaxis, allergic reaction adverse events, use of epinephrine,', 'and accidental and nonaccidental food allergen exposure. Summary statistics will be provided for the', 'Asthma Control Test (ACT), lung function data, and laboratory data if relevant.', 'Other Analyses:', 'Additional endpoints to be assessed over the course of the study include the following:', 'Changes from baseline in Total Nasal Symptom Score (TNSS) scores in subjects with pre-existing', 'allergic rhinitis', 'Changes from baseline in scoring atopic dermatitis (SCORAD) scores in subjects with pre-existing', 'atopic dermatitis', 'Changes in peanut SPT mean wheal diameters', 'Sample Size Considerations:', 'This study will use multiple HRQOL questionnaires to assess changes across time in the HRQOL of subjects', 'receiving AR101 treatment versus standard of care alone and their parents/caregivers.', 'The sample size for this study is based on estimates for the FAQLQ-PF. A sample size of 144 subjects', 'randomly assigned in a ratio of 2:1 to AR101 treatment (96 subjects) or standard of care alone (48 subjects)', 'provides at least 80% power to detect a treatment difference of 0.75 in the adjusted mean total FAQLQ-PF', 'scores at 18 months. The sample size calculation is based on an alpha of 0.05 and tests are assumed to be', '2-sided. The common standard deviation is assumed to be 1.5. Approximately 25% of subjects are', 'estimated to drop out or discontinue early from the study. Therefore, approximately 200 subjects', '(134, AR101 treatment; 67, standard of care alone) will be randomly assigned to study treatment.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 8 of 122', 'TABLE OF CONTENTS', 'SYNOPSIS', '2', 'LIST OF ABBREVIATIONS', '13', '1 INTRODUCTION', '15', '1.1 Background', '15', '1.2 Summary of Relevant Clinical Experience With AR101', '16', '1.2.1 Phase 2 Studies ARC001 and ARC002', '16', '1.2.2 Phase 3 Pivotal Study ARC003', '17', '1.3 Summary of Relevant Nonclinical Experience With AR101', '18', '1.4 AR101 Benefits and Risks Assessment', '18', '1.5 Purpose of the Study', '19', '1.6 Rationale for Study Design', '19', '2', 'STUDY OBJECTIVES', '21', '2.1 Primary Objective', '21', '2.2 Secondary Objectives', '21', '2.3 Exploratory Objectives', '21', '3', 'INVESTIGATIONAL PLAN', '21', '3.1 Overall Study Design and Plan: Description', '21', '3.2 Study Schematic', '23', '3.3 Blinding', '24', '3.4 Duration of Study', '24', '4', 'SELECTION OF STUDY POPULATION', '25', '4.1', 'Inclusion Criteria', '25', '4.2 Exclusion Criteria', '26', '5', 'ENROLLMENT AND STUDY PROCEDURES', '28', '5.1 Screening Period', '28', '5.1.1 Informed Consent', '28', '5.1.2 Subject Identification Numbers', '28', '5.1.3 Screening Procedures', '28', '5.2 Treatment Periods', '29', '5.2.1 Treatment Period Visit Windows', '29', '5.2.2 Randomization Procedures', '29', '5.2.3 General Study Visit Procedures', '29', '5.2.4', 'General Procedures for Subjects Receiving AR101 Treatment', '31', '5.2.4.1 Initial Dose-Escalation Procedures', '32', '5.2.4.2 Up-Dosing Procedures', '34', '5.2.4.3 Maintenance Procedures', '34', '5.2.5 Standard of Care Procedures', '35', '5.2.6 Unscheduled Visit Procedures', '36', '5.3 Early Discontinuation', '36', '5.3.1', 'Follow-Up HRQOL Questionnaires for Subjects Receiving AR101 Treatment Who', 'Discontinue Early', '38', '5.4 Study Exit', '39', '5.5 Safety Follow-Up', '39', '5.5.1 Safety Follow-Up for Subjects With GI Adverse Events of Interest', '40', '5.6 Loss to Follow-Up', '40']\n\n###\n\n", "completion": "END"}